US Edition
Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study
Innovent's Phase 3 trial enrolls 600 Chinese gout patients to compare tigulixostat and febuxostat, addressing safety and efficacy gaps in current treatments.
- On yesterday, Innovent Biologics announced the first participant was dosed in a Phase 3 head-to-head study comparing tigulixostat versus febuxostat for Chinese gout patients.
- Nearly 60% of gout patients in China are aged 18–35 years, and hyperuricemia prevalence reaches 17.7% nationwide, creating urgent demand for safer, more effective therapies.
- Phase 2 data showed tigulixostat 100 mg achieved 81% serum uric acid compliance at 16 weeks, significantly outperforming febuxostat 40 mg with good renal and cardiovascular safety.
- Innovent is building a broader gout portfolio including IBI3011 and mazdutide to address different disease stages; the company in-licensed exclusive China rights from LG Chem in December 2022.
- The randomized, double-blind Phase 3 will enroll 600 Chinese patients receiving tigulixostat 100 mg or febuxostat 40 mg for 24 weeks within a one-year treatment period.
26 Articles
26 Articles
Helena Independent Record
Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study
SAN FRANCISCO and SUZHOU, China, March 22, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other…
Innovent begins phase 3 dosing of gout treatment candidate
SAN FRANCISCO and SUZHOU, China, March 23, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (\"Innovent\", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the xanthine oxidase inhibitor (XOI) Tigulixostat(R&D code: IBI128) have the first participan…
Coverage Details
Bias Distribution
- 93% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
